Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

NCT01903005 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

668

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid Dependence, on Agonist Therapy

Interventions

DRUG: Higher bioavailability BNX sublingual tablets

Sponsor

Orexo AB

Collaborators

[object Object]